WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models - BioLine Rx (NASDAQ:BLRX)

BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.

Raccontata dabenzinga.commorningstar.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
benzinga.comStai leggendo1 mesi fa

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models - BioLine Rx (NASDAQ:BLRX)

BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.

originale
morningstar.com1 mesi fa

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO)…

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 20 maggio 2026·benzinga.com

    BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models - BioLine Rx (NASDAQ:BLRX)

    BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.

  2. venerdì 22 maggio 2026·morningstar.com

    BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

    BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting